查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2127890

活性素訊號抑制劑的市場規模、佔有率、成長率和全球產業分析、區域趨勢和2026年～2034年預測

Activin Signaling Inhibitors Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

活性素訊號抑制劑市場的成長要素

全球活性素訊號抑制劑市場在2025年達到37.3億美元，預計2026年成長至45.5億美元，並在2034年達到118億美元，預測期間內CAGR為11.89%。北美市場將引領全球市場，到2025年佔據45.57%的市場佔有率，這主要得益於創新生物製藥的早期商業化、完善的醫療基礎設施以及對罕見疾病主導投入的增加。

活性素訊號抑制劑正逐漸成為治療與活性素和轉化生長因子-BETA（TGF-BETA）訊號通路異常相關的疾病的極具前景的靶向生物製藥。這些療法在肺動脈高壓（PAH）、血液系統疾病、神經肌肉疾病、肥胖症、代謝性疾病以及多種罕見遺傳性疾病的治療中備受關注。監管部門批准數量的增加、臨床研發管線的擴展以及製藥業的積極投資加速全球市場的成長。

市場趨勢

對罕見疾病治療和精準醫療日益成長的關注是推動活性素訊號抑制劑市場發展的最重要趨勢之一。製藥公司正不斷開發靶向活性素和肌肉生長抑制素通路的單株抗體、配體陷阱和受體融合蛋白，以應對治療選擇有限的疾病。

另一個值得關注的趨勢是，針對肥胖、肌肉量維持和代謝紊亂的臨床研究不斷擴展。多家生技公司研究活性素通路抑制劑，以在減重治療期間維持瘦肌肉量，這為罕見疾病以外的領域開闢了新的商業性機會。

市場促進因素

罕見疾病和特殊疾病的日益增加是市場成長要素。肺動脈高壓、BETA-地中海型貧血、骨髓發育不良症候群進行性肌肉骨化症症（FOP）和脊髓性肌肉萎縮症等疾病需要先進的標靶治療，這些療法不僅可以控制症狀，還可以延緩疾病進展。

此外，孤兒藥監管政策的利多、醫療保健支出的成長、生物製藥應用的日益普及以及對創新藥物研發投入的增加，都持續推動著市場擴張。First-in-Class療法的成功獲批也增強了醫師的信心和市場的接受度。

市場限制因素

儘管成長前景強勁，但由於生物製藥研發成本高昂，市場仍面臨挑戰。單株抗體和受體融合蛋白的研發需要長期的臨床試驗、複雜的生產流程和大量的研發投入。

此外，如果在臨床試驗過程中發現安全性問題，核准可能會延遲，或者有前景的候選藥物的研發可能會終止。高昂的治療費用和有限的保險償付也限制了患者獲得治療的機會，尤其是在新興醫療市場。

市場機會

透過開發孤兒藥和拓展新適應症，該市場蘊藏著巨大的機會。各公司正積極研究活性素通路抑制劑，用於治療肥胖症、肌肉萎縮症、心血管代謝疾病和其他罕見遺傳疾病。

預計在預測期內，特殊生技藥品的溢價定價機會、罕見疾病適應症的快速核准流程以及不斷擴大的研究合作關係將創造有吸引力的長期成長前景。

市場挑戰

主要挑戰之一是獲批商業性的治療方法數量有限。許多活性素訊號抑制劑仍處於臨床研發階段，在醫生廣泛採用之前，還需要更多關於其長期安全性和有效性的資料。

此外，嚴格的監管審查、保險公司的償付要求以及與現有治療方案的競爭仍然是快速商業化的障礙。

細分分析

就藥物類別而言，受已通過核准的受體融合技術療法的商業性成功推動，ActRII配體陷阱和融合蛋白在2025年之前主導市場。同時，由於在多個疾病領域不斷拓展的臨床開發，肌肉生長抑制素/活性素通路抑制劑預計將在預測期內實現最快成長。

就適應症而言，到2025年，血液系統疾病佔據最大的市場佔有率。這主要歸功於活性素通路療法在骨髓發育不良症候群和BETA-地中海貧血相關貧血治療的應用日益廣泛。同時，代謝性疾病和心臟代謝性疾病預計將呈現最高的成長速度，因為各公司日益增加對肥胖症和肌肉功能維持療法的研究力度。

依年齡層別分類，成人市場佔據主導地位，這主要歸因於已通過核准的療法集中於成人患者。依給藥途徑分類，皮下注射因其患者便利性高且適合長期門診治療，佔據了最大的市場佔有率。就通路而言，由於高成本生物製藥需要特殊的給藥和監測，醫院藥房仍然是主要通路。

區域展望

由於快速的法規核准、完善的生物製藥基礎設施和強大的藥物創新能力，北美到2025年市場規模達到17億美元，繼續保持全球最大區域市場的地位。美國市場預計到2026年將達到19.1億美元，繼續維持其全球領先地位。

由於專業生物製藥供應的擴大和有利的法規結構，歐洲預計將經歷強勁成長，到2026年達到 12.4億美元。德國和英國預計將繼續成為該地區的主要貢獻者。

預計到2026年，亞太地區的市場規模將達到 9.1億美元，這主要得益於生物製藥生產投資的增加、人們對罕見疾病的認知不斷提高，以及中國、日本和印度藥物研發的擴張。

在拉丁美洲、中東和非洲地區，由於醫療基礎設施的改善以及在主要醫療機構獲得先進生物製藥療法的機會增加，預計將穩步成長。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢
  • 市場挑戰

第4章 主要考察

  • 主要疾病適應症的盛行率（依主要地區/國家）
  • 主要區域的管道分析
  • 新產品發布：依主要公司分類
  • 主要產業趨勢（合併、收購、合作等）
  • 主要國家的監管和償還趨勢

第5章 2021-2034年全球活性素訊號抑制劑市場分析、洞察與預測

  • 市場分析、洞察與預測：依藥物類別分類
    • ActRII 配體捕獲/融合蛋白
    • 靶向活性素受體的單株抗體
    • 肌肉生長抑制素/活性素路徑抑制劑
    • 其他活性素訊號調節劑
  • 市場分析、洞察與預測：依適應症分類。
    • 血液疾病
    • 心肺疾病
    • 肌肉疾病/神經肌肉疾病
    • 代謝/心血管代謝疾病
    • 其他
  • 市場分析、洞察與預測：依年齡層別分類
    • 兒童
    • 成人
  • 市場分析、洞察與預測：依給藥途徑
    • 皮下
    • 靜脈
    • 其他
  • 市場分析、洞察與預測：依通路分類
    • 醫院藥房
    • 專科藥房
    • 藥局和零售藥房
    • 網路藥房
  • 分析、洞察與預測：依地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美活性素訊號抑制劑市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章 歐洲活性素訊號抑制劑市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章 亞太地區活性素訊號抑制劑市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章 拉丁美洲活性素訊號抑制劑市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章 2021-2034年中東和非洲地區活性素訊號抑制劑市場分析、洞察與預測

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市場佔有率分析（2025年）
  • 公司簡介
    • Bristol Myers Squibb Company
    • Merck & Co., Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Keros Therapeutics, Inc.
    • Takeda Pharmaceutical Company Limited
    • Scholar Rock Holding Corporation
    • Biohaven Ltd.
    • Eli Lilly and Company
    • GSK plc
    • Laekna, Inc.
Product Code: FBI117569

Growth Factors of activin signaling inhibitors Market

The global activin signaling inhibitors market was valued at USD 3.73 billion in 2025 and is expected to grow from USD 4.55 billion in 2026 to USD 11.80 billion by 2034, registering a CAGR of 11.89% during the forecast period. North America dominated the global market with a 45.57% market share in 2025, supported by the early commercialization of innovative biologics, strong healthcare infrastructure, and rising investments in rare disease therapies.

Activin signaling inhibitors are emerging as a promising class of targeted biologic therapies designed to treat disorders associated with abnormal activin and transforming growth factor-beta (TGF-B) signaling pathways. These therapies are gaining significant attention for treating pulmonary arterial hypertension (PAH), hematologic disorders, neuromuscular diseases, obesity, metabolic disorders, and several rare genetic conditions. Increasing regulatory approvals, expanding clinical pipelines, and strong pharmaceutical investments are accelerating market growth worldwide.

Market Trends

The growing focus on rare disease treatment and precision medicine is one of the most influential trends driving the activin signaling inhibitors market. Pharmaceutical companies are increasingly developing monoclonal antibodies, ligand traps, and receptor fusion proteins targeting activin and myostatin pathways to address diseases with limited treatment options.

Another notable trend is the expansion of clinical research into obesity, muscle preservation, and metabolic disorders. Several biotechnology companies are investigating activin pathway inhibitors for preserving lean muscle mass during weight loss therapies, opening new commercial opportunities beyond rare diseases.

Market Drivers

The increasing prevalence of rare and specialty diseases is a major growth driver for the market. Conditions such as pulmonary arterial hypertension, beta-thalassemia, myelodysplastic syndromes, fibrodysplasia ossificans progressiva (FOP), and spinal muscular atrophy require advanced targeted therapies capable of modifying disease progression rather than merely managing symptoms.

Furthermore, favorable regulatory support for orphan drugs, rising healthcare expenditure, growing biologics adoption, and increasing investments in innovative drug development continue to support market expansion. The successful approval of first-in-class therapies has also strengthened physician confidence and commercial acceptance.

Market Restraints

Despite strong growth prospects, the market faces challenges due to the high cost of biologic drug development. Developing monoclonal antibodies and receptor fusion proteins requires lengthy clinical trials, sophisticated manufacturing processes, and significant research investments.

In addition, safety concerns observed during clinical trials may delay approvals or discontinue promising drug candidates. High treatment costs and reimbursement limitations also restrict wider patient access, particularly in emerging healthcare markets.

Market Opportunities

The market offers substantial opportunities through orphan drug development and expansion into new therapeutic indications. Companies are actively exploring activin pathway inhibitors for obesity management, muscle wasting disorders, cardiometabolic diseases, and additional rare genetic disorders.

Premium pricing opportunities for specialty biologics, faster regulatory pathways for orphan indications, and expanding research collaborations are expected to create attractive long-term growth prospects throughout the forecast period.

Market Challenges

One of the major challenges remains the limited number of commercially approved therapies. Most activin signaling inhibitors remain in clinical development, requiring additional long-term safety and efficacy data before achieving widespread physician adoption.

Moreover, stringent regulatory reviews, payer reimbursement requirements, and competition from existing treatment options continue to create barriers to faster commercialization.

Segmentation Analysis

Based on drug class, ActRII ligand traps and fusion proteins dominated the market in 2025 due to the commercial success of approved therapies utilizing receptor-fusion technology. Meanwhile, myostatin/activin pathway inhibitors are projected to record the fastest growth during the forecast period as clinical development expands across multiple disease areas.

By indication, hematologic disorders accounted for the largest market share in 2025, supported by the increasing adoption of activin pathway therapies for anemia associated with myelodysplastic syndromes and beta-thalassemia. Meanwhile, metabolic and cardiometabolic disorders are expected to witness the highest growth as companies expand research into obesity and muscle preservation therapies.

Based on age group, the adult segment dominated the market due to the concentration of approved therapies targeting adult patients. By route of administration, subcutaneous injections held the largest share because of improved patient convenience and suitability for long-term outpatient treatment. In terms of distribution channels, hospital pharmacies remained the leading segment owing to the specialist administration and monitoring requirements associated with high-cost biologic therapies.

Regional Outlook

North America remained the largest regional market, reaching USD 1.70 billion in 2025, driven by rapid regulatory approvals, advanced biologics infrastructure, and strong pharmaceutical innovation. The U.S. market is expected to reach USD 1.91 billion in 2026, maintaining its leadership position globally.

Europe is projected to experience strong growth, reaching USD 1.24 billion in 2026, supported by expanding access to specialty biologics and favorable regulatory frameworks. Germany and the U.K. continue to be major regional contributors.

Asia Pacific is expected to reach USD 0.91 billion in 2026, driven by increasing investments in biologics manufacturing, rare disease awareness, and expanding pharmaceutical research across China, Japan, and India.

Latin America together with the Middle East & Africa are anticipated to witness steady growth as healthcare infrastructure improves and access to advanced biologic therapies expands across major healthcare centers.

Competitive Landscape

The activin signaling inhibitors market remains semi-consolidated, with leading pharmaceutical companies investing heavily in clinical development, regulatory approvals, acquisitions, and strategic partnerships. Major companies include Bristol Myers Squibb Company, Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., Keros Therapeutics, Takeda Pharmaceutical Company Limited, Scholar Rock Holding Corporation, Biohaven Ltd., Eli Lilly and Company, GSK plc, and Laekna, Inc.

Recent product approvals, expanding Phase II and Phase III clinical programs, and ongoing innovation in targeted biologics are strengthening competitive positioning while creating new commercial opportunities across multiple therapeutic areas.

Conclusion

The global activin signaling inhibitors market is positioned for robust expansion as targeted biologic therapies become increasingly important in treating rare diseases, hematologic disorders, pulmonary arterial hypertension, metabolic disorders, and neuromuscular conditions. Valued at USD 3.73 billion in 2025, the market is forecast to grow to USD 4.55 billion in 2026 and reach USD 11.80 billion by 2034, reflecting strong long-term demand. Continued regulatory approvals, expanding clinical pipelines, advances in biologics research, and growing investment in precision medicine are expected to drive sustained market growth throughout the forecast period.

Segmentation By Drug Class, Indication, Age Group, Route of Administration, Distribution Channel, and Region

By Drug Class * ActRII Ligand Traps/Fusion Proteins

  • Activin Receptor-Targeting Monoclonal Antibodies
  • Myostatin/Activin Pathway Inhibitors
  • Other Activin-Signaling Modulators

By Indication * Hematologic Disorders

  • Cardiopulmonary Disorders
  • Muscle/Neuromuscular Disorders
  • Metabolic/Cardiometabolic disorders
  • Others

By Age Group * Pediatric

  • Adults

By Route of Administration * Subcutaneous

  • Intravenous
  • Others

By Distribution Channel * Hospital Pharmacies

  • Specialty Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region * North America (By Drug Class, Indication, Age Group, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Drug Class, Indication, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Indication, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Indication, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Indication, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends
  • 3.5. Market Challenges

4. Key Insights

  • 4.1. Prevalence of Key Disease Indications, By Key Regions/Countries
  • 4.2. Pipeline Analysis, By Key Regions
  • 4.3. New Product Launches, By Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.5. Regulatory & Reimbursement Scenario, By Key Countries

5. Global Activin Signaling Inhibitors Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. ActRII Ligand Traps/Fusion Proteins
    • 5.1.2. Activin Receptor-Targeting Monoclonal Antibodies
    • 5.1.3. Myostatin/Activin Pathway Inhibitors
    • 5.1.4. Other Activin-Signaling Modulators
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. Hematologic Disorders
    • 5.2.2. Cardiopulmonary Disorders
    • 5.2.3. Muscle/Neuromuscular Disorders
    • 5.2.4. Metabolic/Cardiometabolic disorders
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adults
  • 5.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.4.1. Subcutaneous
    • 5.4.2. Intravenous
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Specialty Pharmacies
    • 5.5.3. Drug Stores & Retail Pharmacies
    • 5.5.4. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Activin Signaling Inhibitors Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. ActRII Ligand Traps/Fusion Proteins
    • 6.1.2. Activin Receptor-Targeting Monoclonal Antibodies
    • 6.1.3. Myostatin/Activin Pathway Inhibitors
    • 6.1.4. Other Activin-Signaling Modulators
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. Hematologic Disorders
    • 6.2.2. Cardiopulmonary Disorders
    • 6.2.3. Muscle/Neuromuscular Disorders
    • 6.2.4. Metabolic/Cardiometabolic disorders
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adults
  • 6.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.4.1. Subcutaneous
    • 6.4.2. Intravenous
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Specialty Pharmacies
    • 6.5.3. Drug Stores & Retail Pharmacies
    • 6.5.4. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Activin Signaling Inhibitors Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. ActRII Ligand Traps/Fusion Proteins
    • 7.1.2. Activin Receptor-Targeting Monoclonal Antibodies
    • 7.1.3. Myostatin/Activin Pathway Inhibitors
    • 7.1.4. Other Activin-Signaling Modulators
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. Hematologic Disorders
    • 7.2.2. Cardiopulmonary Disorders
    • 7.2.3. Muscle/Neuromuscular Disorders
    • 7.2.4. Metabolic/Cardiometabolic disorders
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adults
  • 7.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.4.1. Subcutaneous
    • 7.4.2. Intravenous
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Specialty Pharmacies
    • 7.5.3. Drug Stores & Retail Pharmacies
    • 7.5.4. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Activin Signaling Inhibitors Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. ActRII Ligand Traps/Fusion Proteins
    • 8.1.2. Activin Receptor-Targeting Monoclonal Antibodies
    • 8.1.3. Myostatin/Activin Pathway Inhibitors
    • 8.1.4. Other Activin-Signaling Modulators
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. Hematologic Disorders
    • 8.2.2. Cardiopulmonary Disorders
    • 8.2.3. Muscle/Neuromuscular Disorders
    • 8.2.4. Metabolic/Cardiometabolic disorders
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adults
  • 8.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.4.1. Subcutaneous
    • 8.4.2. Intravenous
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Specialty Pharmacies
    • 8.5.3. Drug Stores & Retail Pharmacies
    • 8.5.4. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Southeast Asia
    • 8.6.5. Australia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Activin Signaling Inhibitors Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. ActRII Ligand Traps/Fusion Proteins
    • 9.1.2. Activin Receptor-Targeting Monoclonal Antibodies
    • 9.1.3. Myostatin/Activin Pathway Inhibitors
    • 9.1.4. Other Activin-Signaling Modulators
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. Hematologic Disorders
    • 9.2.2. Cardiopulmonary Disorders
    • 9.2.3. Muscle/Neuromuscular Disorders
    • 9.2.4. Metabolic/Cardiometabolic disorders
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adults
  • 9.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.4.1. Subcutaneous
    • 9.4.2. Intravenous
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Specialty Pharmacies
    • 9.5.3. Drug Stores & Retail Pharmacies
    • 9.5.4. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Activin Signaling Inhibitors Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. ActRII Ligand Traps/Fusion Proteins
    • 10.1.2. Activin Receptor-Targeting Monoclonal Antibodies
    • 10.1.3. Myostatin/Activin Pathway Inhibitors
    • 10.1.4. Other Activin-Signaling Modulators
  • 10.2. Market Analysis, Insights and Forecast - By Indication
    • 10.2.1. Hematologic Disorders
    • 10.2.2. Cardiopulmonary Disorders
    • 10.2.3. Muscle/Neuromuscular Disorders
    • 10.2.4. Metabolic/Cardiometabolic disorders
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adults
  • 10.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.4.1. Subcutaneous
    • 10.4.2. Intravenous
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Specialty Pharmacies
    • 10.5.3. Drug Stores & Retail Pharmacies
    • 10.5.4. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Bristol Myers Squibb Company
    • 11.2.2. Merck & Co., Inc.
    • 11.2.3. Regeneron Pharmaceuticals, Inc.
    • 11.2.4. Keros Therapeutics, Inc.
    • 11.2.5. Takeda Pharmaceutical Company Limited
    • 11.2.6. Scholar Rock Holding Corporation
    • 11.2.7. Biohaven Ltd.
    • 11.2.8. Eli Lilly and Company
    • 11.2.9. GSK plc
    • 11.2.10. Laekna, Inc.

List of Tables

  • Table 1: Global Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 3: Global Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 4: Global Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 5: Global Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 8: North America Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 9: North America Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 10: North America Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 11: North America Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 13: Europe Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 14: Europe Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 15: Europe Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 16: Europe Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 17: Europe Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Europe Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 20: Asia Pacific Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 21: Asia Pacific Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 22: Asia Pacific Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 23: Asia Pacific Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Asia Pacific Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 25: Latin America Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 26: Latin America Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 27: Latin America Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 28: Latin America Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 29: Latin America Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Latin America Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 32: Middle East & Africa Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 33: Middle East & Africa Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 34: Middle East & Africa Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 35: Middle East & Africa Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 36: Middle East & Africa Activin Signaling Inhibitors Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Activin Signaling Inhibitors Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Activin Signaling Inhibitors Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Activin Signaling Inhibitors Market Value Share (%), by Indication, 2025 & 2034
  • Figure 4: Global Activin Signaling Inhibitors Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 5: Global Activin Signaling Inhibitors Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 6: Global Activin Signaling Inhibitors Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global Activin Signaling Inhibitors Market Value Share (%), by Region, 2025 & 2034
  • Figure 8: North America Activin Signaling Inhibitors Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 9: North America Activin Signaling Inhibitors Market Value Share (%), by Drug Class, 2025
  • Figure 10: North America Activin Signaling Inhibitors Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 11: North America Activin Signaling Inhibitors Market Value Share (%), by Indication, 2025
  • Figure 12: North America Activin Signaling Inhibitors Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 13: North America Activin Signaling Inhibitors Market Value Share (%), by Age Group 2025
  • Figure 14: North America Activin Signaling Inhibitors Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 15: North America Activin Signaling Inhibitors Market Value Share (%), by Route of Administration, 2025
  • Figure 16: North America Activin Signaling Inhibitors Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America Activin Signaling Inhibitors Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America Activin Signaling Inhibitors Market Value (USD billion), by Country, 2025 & 2034
  • Figure 19: North America Activin Signaling Inhibitors Market Value Share (%), by Country, 2025
  • Figure 20: Europe Activin Signaling Inhibitors Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 21: Europe Activin Signaling Inhibitors Market Value Share (%), by Drug Class, 2025
  • Figure 22: Europe Activin Signaling Inhibitors Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 23: Europe Activin Signaling Inhibitors Market Value Share (%), by Indication, 2025
  • Figure 24: Europe Activin Signaling Inhibitors Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 25: Europe Activin Signaling Inhibitors Market Value Share (%), by Age Group 2025
  • Figure 26: Europe Activin Signaling Inhibitors Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 27: Europe Activin Signaling Inhibitors Market Value Share (%), by Route of Administration, 2025
  • Figure 28: Europe Activin Signaling Inhibitors Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Activin Signaling Inhibitors Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Activin Signaling Inhibitors Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Activin Signaling Inhibitors Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Activin Signaling Inhibitors Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 33: Asia Pacific Activin Signaling Inhibitors Market Value Share (%), by Drug Class, 2025
  • Figure 34: Asia Pacific Activin Signaling Inhibitors Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 35: Asia Pacific Activin Signaling Inhibitors Market Value Share (%), by Indication, 2025
  • Figure 36: Asia Pacific Activin Signaling Inhibitors Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 37: Asia Pacific Activin Signaling Inhibitors Market Value Share (%), by Age Group 2025
  • Figure 38: Asia Pacific Activin Signaling Inhibitors Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 39: Asia Pacific Activin Signaling Inhibitors Market Value Share (%), by Route of Administration, 2025
  • Figure 40: Asia Pacific Activin Signaling Inhibitors Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific Activin Signaling Inhibitors Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific Activin Signaling Inhibitors Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Activin Signaling Inhibitors Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 44: Latin America Activin Signaling Inhibitors Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 45: Latin America Activin Signaling Inhibitors Market Value Share (%), by Drug Class, 2025
  • Figure 46: Latin America Activin Signaling Inhibitors Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 47: Latin America Activin Signaling Inhibitors Market Value Share (%), by Indication, 2025
  • Figure 48: Latin America Activin Signaling Inhibitors Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 49: Latin America Activin Signaling Inhibitors Market Value Share (%), by Age Group 2025
  • Figure 50: Latin America Activin Signaling Inhibitors Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 51: Latin America Activin Signaling Inhibitors Market Value Share (%), by Route of Administration, 2025
  • Figure 52: Latin America Activin Signaling Inhibitors Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America Activin Signaling Inhibitors Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America Activin Signaling Inhibitors Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Activin Signaling Inhibitors Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Activin Signaling Inhibitors Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 57: Middle East & Africa Activin Signaling Inhibitors Market Value Share (%), by Drug Class, 2025
  • Figure 58: Middle East & Africa Activin Signaling Inhibitors Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 59: Middle East & Africa Activin Signaling Inhibitors Market Value Share (%), by Indication, 2025
  • Figure 60: Middle East & Africa Activin Signaling Inhibitors Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 61: Middle East & Africa Activin Signaling Inhibitors Market Value Share (%), by Age Group 2025
  • Figure 62: Middle East & Africa Activin Signaling Inhibitors Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 63: Middle East & Africa Activin Signaling Inhibitors Market Value Share (%), by Route of Administration, 2025
  • Figure 64: Middle East & Africa Activin Signaling Inhibitors Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa Activin Signaling Inhibitors Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Activin Signaling Inhibitors Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Activin Signaling Inhibitors Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 68: Global Activin Signaling Inhibitors Market Share (%), by Company, 2025